You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

CHMP recommends Idorsia’s dual acting treatment Quviviq for insomnia patients

The Committee for Medicinal Products for Human Use (CHMP) has recommended Quviviq (daridorexant) as the first dual orexin receptor antagonist in the EU for the treatment of adult patients with insomnia.